In 2019, Chira’s group proposed an innovative idea for the highly tumor-specific delivery of TP53 to replace the mutant TP53 gene with a functional copy in tumor cells, resulting in sustained expression of the undruggable p53 protein and tumor regression.581 In the meantime, Huang and Liu’s group constructed a p53 genetic sensor compound (247), and combined it with diphtheria toxin using the CRISPR-Cas9 system to specifically eliminate p53-deficient cells. This evidence concerns the gene TP53 and neoplasm.